Real‐World 10‐Year Outcomes of Anti‐ VEGF Therapy for Neovascular Age‐Related Macular Degeneration: A Meta‐Analysis
Clinical & Experimental Ophthalmology · 2025-09 · 53 (7) · 773-790
DOI: 10.1111/ceo.14559 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Clinical & Experimental Ophthalmology, online erschienen am 24.05.2025. Verfasst von Kimberly Spooner und 5 weiteren Autor:innen. Beteiligte Einrichtung: Cureos Research, Sydney, Australia. Hauptthemen laut MEDLINE: Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Wet Macular Degeneration. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
This study examines the long‐term effectiveness of anti‐VEGF therapy in managing neovascular age‐related macular degeneration (nAMD). Despite the well‐established short‐term improvements of anti‐VEGF therapy, there is limited data on its continued efficacy over extended periods. This meta‐analysis synthesises real‐world data to evaluate anti‐VEGF therapy's long‐term outcomes systematically.
Methods
We conducted a comprehensive literature review across PubMed, EMBASE and Cochrane databases, focusing on studies that reported outcomes of anti‐VEGF treatment for nAMD over a decade. The analysis included pooling baseline patient characteristics, study designs, sample sizes and changes in visual acuity (VA) over 10 years.
Results
Our search produced 12 observational studies encompassing 7509 eyes, with 1274 completing 10‐years of follow‐up. The most substantial improvement in VA was observed in the first year following the initiation of anti‐VEGF therapy. On average, there was a decline of 8.11 letters in VA after 10 years from baseline (95% CI −10.83 to −5.39, p < 0.01). In some cases, VA reverted to baseline levels after 10 years; in others, it declined significantly below baseline. Meta‐regression showed that mean VA change was greater in those with a lower baseline VA and those treated with a higher number of injections over 10‐years( p < 0.01).
Conclusion
Our findings suggest that the mean visual acuity of eyes treated for nAMD deteriorates progressively over the long‐term from two years after starting treatment. Regular injections appear crucial for preserving maximum vision. While our analysis did not identify an increased incidence of serious ocular adverse events, the long‐term impact of anti‐VEGF therapy on geographic atrophy remains unclear and warrants further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cureos Research, Sydney, Australia.
- Save Sight Institute, University of Sydney, Sydney, Australia.
- Graduate School of Health, The University of Technology, Sydney, Australia.
- Canberra Eye Surgeons, Canberra, Australia.
- Sydney Eye Hospital, Sydney, Australia.
- Royal North Shore Hospital, St Leonards, Australia.
ORCID-Profile: Geoffrey Broadhead, Samantha Fraser-Bell, Andrew A Chang
Zitieren
APA
Spooner, K., Broadhead, G., Fraser-Bell, S., Hong, T., Wong, J. G., & Chang, A. A. (2025). Real‐World 10‐Year Outcomes of Anti‐ VEGF Therapy for Neovascular Age‐Related Macular Degeneration: A Meta‐Analysis. Clinical & Experimental Ophthalmology, 53(7), 773-790. https://doi.org/10.1111/ceo.14559
Vancouver
Spooner K, Broadhead G, Fraser-Bell S, Hong T, Wong JG, Chang AA. Real‐World 10‐Year Outcomes of Anti‐ VEGF Therapy for Neovascular Age‐Related Macular Degeneration: A Meta‐Analysis. Clinical & Experimental Ophthalmology. 2025;53(7):773-790. doi:10.1111/ceo.14559
BibTeX
@article{Spooner2025,
author = {Spooner, Kimberly and Broadhead, Geoffrey and Fraser-Bell, Samantha and Hong, Thomas and Wong, James G and Chang, Andrew A},
title = {Real‐World 10‐Year Outcomes of Anti‐ VEGF Therapy for Neovascular Age‐Related Macular Degeneration: A Meta‐Analysis},
journal = {Clinical & Experimental Ophthalmology},
year = {2025},
volume = {53},
number = {7},
pages = {773--790},
doi = {10.1111/ceo.14559}
}
EUVIMED